Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 890 participants.

Also called NCT05385770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 890 participants (enrolled count) (from the registry)
Sponsor
  • Celltrion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05385770
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05385770. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2024-07-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
Condition
Essential Hypertension
Intervention (Drug)
AZM X mg + AML Y mg
Intervention (Drug)
AZM X mg + AML Y' mg
Intervention (Drug)
AZM X' mg + AML Y mg
Intervention (Drug)
AZM X' mg + AML Y' mg
Intervention (Drug)
AZM X mg
Intervention (Drug)
AZM X' mg
Intervention (Drug)
AML Y mg
Intervention (Drug)
AML Y' mg
Lead sponsor
Celltrion (class: industry)

Record details

Record id
cardio:ct-nct05385770
Content hash
0b7dac92106b0b774665cf3980f495bee7e5e00d7836df6c2999f6abaadbb821